JAMA|2026|Anderer S
PMID: 42065899
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
OBJECTIVES: To investigate the clinical characteristics of weight loss drugs (WLDs) users in Norway. DESIGN: Nested population-based case-control study. SETTING: Nationwide healthcare registries with data on dispensed medications and healthcare diagn…
AIMS: Tirzepatide, an injectable glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP-1 RAs, such as semaglutide, are under invest…
BACKGROUND: Real-world data directly comparing the safety, tolerability, and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited. This nationwide multicenter observational study compared short-term adverse events, tre…
OBJECTIVE: Semaglutide improves cardiovascular disease (CVD) risk in people who are diabetic, overweight or obese through incompletely understood mechanisms. To address this, we explored novel lipidomic and lipo-/glyco-protein profiling with semaglut…
Congenital cytomegalovirus (CMV) infection, due to both nonprimary and primary maternal infection, affects nearly 1% of neonates. In conducting a randomized trial of hyperimmune globulin for prevention of congenital CMV infection, we screened over 20…
Glucagon-like peptide 1 receptor (GLP1R) agonists, such as semaglutide, drive weight loss by binding to GLP1Rs-classically described as G-coupled G-protein-coupled receptors-in the brain; however, the intracellular signalling mechanisms underlying th…
Glucagon-like peptide-1 receptor agonists are widely used for the management of obesity and dysglycaemia, and current evidence does not support a causal association with pancreatic cancer. We report a 55-year old woman with obesity and prediabetes wh…
AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent worldwide and may progress to metabolic dysfunction-associated steatohepatitis (MASH), advanced fibrosis, cirrhosis, and hepatocellular carcinoma, yet effectiv…
Glucagon-like peptide-1 (GLP-1)-based obesity pharmacotherapies have revolutionized obesity treatment. In this review, we discuss the discovery of GLP-1 and evaluate the efficacy of marketed and investigational GLP-1 receptor (GLP-1R) agonists (GLP-1…
Two out of 5 US adults live with obesity, generating substantial clinical and economic burden. Recent glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, demonstrate significant weight loss and cardiometaboli…
Severe obesity is a relative exclusion criterion for heart transplantation. This study assessed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss as a bridge to heart transplantation candidacy. A retrospective study of end-stage h…
The prevalence of type 2 diabetes mellitus has been rising continuously in China. However, glycemic control rates remain suboptimal, posing a significant public health challenge. Although traditional intensive insulin strategies are effective in impr…
INTRODUCTION: Cocaine use disorder (CUD) is a significant public health concern in the USA, with considerable prevalence and mortality and no Food and Drug Administration (FDA)-approved pharmacotherapies. Recent advances in addiction science emphasis…
PurposeThe rapid growth of semaglutide use for weight loss has been accompanied by a proliferation of patient-shared experiences and non-evidence-based claims on video platforms. This unchecked information environment poses significant risks to publi…
BACKGROUND AND AIM: Semaglutide therapy improves glycaemic control, weight loss, and cardiovascular risk reduction in patients with type 2 diabetes mellitus (T2D). Sex-specific differences in the response to oral versus subcutaneous formulation remai…